Management of patients with multidrugresistant/ extensively drug-resistant tuberculosis in Europe

A TBNET consensus statement

Christoph Lange, Ibrahim Abubakar, Jan Willem C Alffenaar, Graham Bothamley, Jose A. Caminero, Anna Cristina C Carvalho, Kwok Chiu Chang, Luigi Codecasa, Ana Correia, Valeriu Crudu, Peter Davies, Martin Dedicoat, Francis Drobniewski, Raquel Duarte, Cordula Ehlers, Connie Erkens, Delia Goletti, Gunar Günther, Elmira Ibraim, Beate Kampmann & 20 others Liga Kuksa, Wiel De Lange, Frank Van Leth, Jan Van Lunzen, Alberto Matteelli, Dick Menzies, Ignacio Monedero, Elvira Richter, Sabine Rüsch-Gerdes, Andreas Sandgren, Anna Scardigli, Alena Skrahina, Enrico Tortoli, Grigory Volchenkov, Dirk Wagner, Marieke J. Van Der Werf, Bhanu Williams, Wing Wai Yew, Jean Pierre Zellweger, Daniela Maria Cirillo

Research output: Contribution to journalArticle

170 Citations (Scopus)

Abstract

The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) substantially challenges TB control, especially in the European Region of the World Health Organization, where the highest prevalence of MDR/XDR cases is reported. The current management of patients with MDR/XDR-TB is extremely complex for medical, social and public health systems. The treatment with currently available anti-TB therapies to achieve relapse-free cure is long and undermined by a high frequency of adverse drug events, suboptimal treatment adherence, high costs and low treatment success rates. Availability of optimal management for patients with MDR/XDR-TB is limited even in the European Region. In the absence of a preventive vaccine, more effective diagnostic tools and novel therapeutic interventions the control of MDR/XDR-TB will be extremely difficult. Despite recent scientific advances in MDR/XDR-TB care, decisions for the management of patients with MDR/XDR-TB and their contacts often rely on expert opinions, rather than on clinical evidence. This document summarises the current knowledge on the prevention, diagnosis and treatment of adults and children with MDR/XDR-TB and their contacts, and provides expert consensus recommendations on questions where scientific evidence is still lacking.

Original languageEnglish
Pages (from-to)23-63
Number of pages41
JournalEuropean Respiratory Journal
Volume44
Issue number1
DOIs
Publication statusPublished - Jul 1 2014

Fingerprint

Extensively Drug-Resistant Tuberculosis
Multidrug-Resistant Tuberculosis
Tuberculosis
Patient Care Management
Therapeutics
Expert Testimony
Drug-Related Side Effects and Adverse Reactions
Health Care Costs
Vaccines
Public Health
Recurrence

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Management of patients with multidrugresistant/ extensively drug-resistant tuberculosis in Europe : A TBNET consensus statement. / Lange, Christoph; Abubakar, Ibrahim; Alffenaar, Jan Willem C; Bothamley, Graham; Caminero, Jose A.; Carvalho, Anna Cristina C; Chang, Kwok Chiu; Codecasa, Luigi; Correia, Ana; Crudu, Valeriu; Davies, Peter; Dedicoat, Martin; Drobniewski, Francis; Duarte, Raquel; Ehlers, Cordula; Erkens, Connie; Goletti, Delia; Günther, Gunar; Ibraim, Elmira; Kampmann, Beate; Kuksa, Liga; De Lange, Wiel; Van Leth, Frank; Van Lunzen, Jan; Matteelli, Alberto; Menzies, Dick; Monedero, Ignacio; Richter, Elvira; Rüsch-Gerdes, Sabine; Sandgren, Andreas; Scardigli, Anna; Skrahina, Alena; Tortoli, Enrico; Volchenkov, Grigory; Wagner, Dirk; Van Der Werf, Marieke J.; Williams, Bhanu; Yew, Wing Wai; Zellweger, Jean Pierre; Cirillo, Daniela Maria.

In: European Respiratory Journal, Vol. 44, No. 1, 01.07.2014, p. 23-63.

Research output: Contribution to journalArticle

Lange, C, Abubakar, I, Alffenaar, JWC, Bothamley, G, Caminero, JA, Carvalho, ACC, Chang, KC, Codecasa, L, Correia, A, Crudu, V, Davies, P, Dedicoat, M, Drobniewski, F, Duarte, R, Ehlers, C, Erkens, C, Goletti, D, Günther, G, Ibraim, E, Kampmann, B, Kuksa, L, De Lange, W, Van Leth, F, Van Lunzen, J, Matteelli, A, Menzies, D, Monedero, I, Richter, E, Rüsch-Gerdes, S, Sandgren, A, Scardigli, A, Skrahina, A, Tortoli, E, Volchenkov, G, Wagner, D, Van Der Werf, MJ, Williams, B, Yew, WW, Zellweger, JP & Cirillo, DM 2014, 'Management of patients with multidrugresistant/ extensively drug-resistant tuberculosis in Europe: A TBNET consensus statement', European Respiratory Journal, vol. 44, no. 1, pp. 23-63. https://doi.org/10.1183/09031936.00188313
Lange, Christoph ; Abubakar, Ibrahim ; Alffenaar, Jan Willem C ; Bothamley, Graham ; Caminero, Jose A. ; Carvalho, Anna Cristina C ; Chang, Kwok Chiu ; Codecasa, Luigi ; Correia, Ana ; Crudu, Valeriu ; Davies, Peter ; Dedicoat, Martin ; Drobniewski, Francis ; Duarte, Raquel ; Ehlers, Cordula ; Erkens, Connie ; Goletti, Delia ; Günther, Gunar ; Ibraim, Elmira ; Kampmann, Beate ; Kuksa, Liga ; De Lange, Wiel ; Van Leth, Frank ; Van Lunzen, Jan ; Matteelli, Alberto ; Menzies, Dick ; Monedero, Ignacio ; Richter, Elvira ; Rüsch-Gerdes, Sabine ; Sandgren, Andreas ; Scardigli, Anna ; Skrahina, Alena ; Tortoli, Enrico ; Volchenkov, Grigory ; Wagner, Dirk ; Van Der Werf, Marieke J. ; Williams, Bhanu ; Yew, Wing Wai ; Zellweger, Jean Pierre ; Cirillo, Daniela Maria. / Management of patients with multidrugresistant/ extensively drug-resistant tuberculosis in Europe : A TBNET consensus statement. In: European Respiratory Journal. 2014 ; Vol. 44, No. 1. pp. 23-63.
@article{fdf5fa2f92f94bb0b22d8ba6d18f705c,
title = "Management of patients with multidrugresistant/ extensively drug-resistant tuberculosis in Europe: A TBNET consensus statement",
abstract = "The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) substantially challenges TB control, especially in the European Region of the World Health Organization, where the highest prevalence of MDR/XDR cases is reported. The current management of patients with MDR/XDR-TB is extremely complex for medical, social and public health systems. The treatment with currently available anti-TB therapies to achieve relapse-free cure is long and undermined by a high frequency of adverse drug events, suboptimal treatment adherence, high costs and low treatment success rates. Availability of optimal management for patients with MDR/XDR-TB is limited even in the European Region. In the absence of a preventive vaccine, more effective diagnostic tools and novel therapeutic interventions the control of MDR/XDR-TB will be extremely difficult. Despite recent scientific advances in MDR/XDR-TB care, decisions for the management of patients with MDR/XDR-TB and their contacts often rely on expert opinions, rather than on clinical evidence. This document summarises the current knowledge on the prevention, diagnosis and treatment of adults and children with MDR/XDR-TB and their contacts, and provides expert consensus recommendations on questions where scientific evidence is still lacking.",
author = "Christoph Lange and Ibrahim Abubakar and Alffenaar, {Jan Willem C} and Graham Bothamley and Caminero, {Jose A.} and Carvalho, {Anna Cristina C} and Chang, {Kwok Chiu} and Luigi Codecasa and Ana Correia and Valeriu Crudu and Peter Davies and Martin Dedicoat and Francis Drobniewski and Raquel Duarte and Cordula Ehlers and Connie Erkens and Delia Goletti and Gunar G{\"u}nther and Elmira Ibraim and Beate Kampmann and Liga Kuksa and {De Lange}, Wiel and {Van Leth}, Frank and {Van Lunzen}, Jan and Alberto Matteelli and Dick Menzies and Ignacio Monedero and Elvira Richter and Sabine R{\"u}sch-Gerdes and Andreas Sandgren and Anna Scardigli and Alena Skrahina and Enrico Tortoli and Grigory Volchenkov and Dirk Wagner and {Van Der Werf}, {Marieke J.} and Bhanu Williams and Yew, {Wing Wai} and Zellweger, {Jean Pierre} and Cirillo, {Daniela Maria}",
year = "2014",
month = "7",
day = "1",
doi = "10.1183/09031936.00188313",
language = "English",
volume = "44",
pages = "23--63",
journal = "European Journal of Respiratory Diseases",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "1",

}

TY - JOUR

T1 - Management of patients with multidrugresistant/ extensively drug-resistant tuberculosis in Europe

T2 - A TBNET consensus statement

AU - Lange, Christoph

AU - Abubakar, Ibrahim

AU - Alffenaar, Jan Willem C

AU - Bothamley, Graham

AU - Caminero, Jose A.

AU - Carvalho, Anna Cristina C

AU - Chang, Kwok Chiu

AU - Codecasa, Luigi

AU - Correia, Ana

AU - Crudu, Valeriu

AU - Davies, Peter

AU - Dedicoat, Martin

AU - Drobniewski, Francis

AU - Duarte, Raquel

AU - Ehlers, Cordula

AU - Erkens, Connie

AU - Goletti, Delia

AU - Günther, Gunar

AU - Ibraim, Elmira

AU - Kampmann, Beate

AU - Kuksa, Liga

AU - De Lange, Wiel

AU - Van Leth, Frank

AU - Van Lunzen, Jan

AU - Matteelli, Alberto

AU - Menzies, Dick

AU - Monedero, Ignacio

AU - Richter, Elvira

AU - Rüsch-Gerdes, Sabine

AU - Sandgren, Andreas

AU - Scardigli, Anna

AU - Skrahina, Alena

AU - Tortoli, Enrico

AU - Volchenkov, Grigory

AU - Wagner, Dirk

AU - Van Der Werf, Marieke J.

AU - Williams, Bhanu

AU - Yew, Wing Wai

AU - Zellweger, Jean Pierre

AU - Cirillo, Daniela Maria

PY - 2014/7/1

Y1 - 2014/7/1

N2 - The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) substantially challenges TB control, especially in the European Region of the World Health Organization, where the highest prevalence of MDR/XDR cases is reported. The current management of patients with MDR/XDR-TB is extremely complex for medical, social and public health systems. The treatment with currently available anti-TB therapies to achieve relapse-free cure is long and undermined by a high frequency of adverse drug events, suboptimal treatment adherence, high costs and low treatment success rates. Availability of optimal management for patients with MDR/XDR-TB is limited even in the European Region. In the absence of a preventive vaccine, more effective diagnostic tools and novel therapeutic interventions the control of MDR/XDR-TB will be extremely difficult. Despite recent scientific advances in MDR/XDR-TB care, decisions for the management of patients with MDR/XDR-TB and their contacts often rely on expert opinions, rather than on clinical evidence. This document summarises the current knowledge on the prevention, diagnosis and treatment of adults and children with MDR/XDR-TB and their contacts, and provides expert consensus recommendations on questions where scientific evidence is still lacking.

AB - The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) substantially challenges TB control, especially in the European Region of the World Health Organization, where the highest prevalence of MDR/XDR cases is reported. The current management of patients with MDR/XDR-TB is extremely complex for medical, social and public health systems. The treatment with currently available anti-TB therapies to achieve relapse-free cure is long and undermined by a high frequency of adverse drug events, suboptimal treatment adherence, high costs and low treatment success rates. Availability of optimal management for patients with MDR/XDR-TB is limited even in the European Region. In the absence of a preventive vaccine, more effective diagnostic tools and novel therapeutic interventions the control of MDR/XDR-TB will be extremely difficult. Despite recent scientific advances in MDR/XDR-TB care, decisions for the management of patients with MDR/XDR-TB and their contacts often rely on expert opinions, rather than on clinical evidence. This document summarises the current knowledge on the prevention, diagnosis and treatment of adults and children with MDR/XDR-TB and their contacts, and provides expert consensus recommendations on questions where scientific evidence is still lacking.

UR - http://www.scopus.com/inward/record.url?scp=84902185616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902185616&partnerID=8YFLogxK

U2 - 10.1183/09031936.00188313

DO - 10.1183/09031936.00188313

M3 - Article

VL - 44

SP - 23

EP - 63

JO - European Journal of Respiratory Diseases

JF - European Journal of Respiratory Diseases

SN - 0903-1936

IS - 1

ER -